Early results from major clinical trial show healthy lifestyle slows cognitive decline
Her focus on exercise is light-years away from where Jones, 66, of Aurora, Illinois, was just a few years ago. She had prediabetes, and her cholesterol and blood pressure levels were inching up.
She was totally sedentary after falling into deep depression. 'I was in bed. I didn't care at all. I was just spiraling,' Jones said.
She was probably also destined to lose her ability to think clearly.
Jones' mother and grandmother died of vascular dementia, a condition that occurs when the body can't pump enough blood to the brain. Other family members had the disease, too.
'Watching two generations suffer made me determined to break the cycle for myself,' Jones said. 'I'm not that person anymore.'
Four years ago, Jones joined a major clinical trial, called U.S. POINTER, that aimed to figure out how older adults at high risk for dementia can stay healthier longer.
Half of the more than 2,000 participants were given advice on a healthy lifestyle, including diet and exercise. The other half was thrust into a structured, team-based program that gave participants goals to transform their lifestyles. The program included meeting with experts and other participants regularly, as well as brain exercises and aerobics classes. Participants were instructed to follow the MIND diet, which trades processed foods for whole grains, fruits, leafy greens and other vegetables.
The researchers evaluated cognitive function by measuring memory, the ability to focus while juggling multiple tasks, and how quickly people interpreted and responded to information.
After two years, both groups showed progress. But people in the structured group saw greater benefits.
'Our conservative estimate shows that, relative to the self-guided group, the structured group performed at a level comparable to adults who were one to two years younger in age,' said Laura Baker, lead researcher and a gerontology professor at Wake Forest University School of Medicine and Advocate Health in Winston-Salem, North Carolina.
'This is what's giving folks additional resilience against cognitive decline,' she said.
Greater support and accountability in the structured group were key benefits.
'We're going to tell you what to do, but we're also going to help you get there, and we're going to work with you as a partner to meet you where you are,' Baker said during a news briefing about the findings Monday at the Alzheimer's Association International Conference in Toronto.
The research, published simultaneously in the Journal of the American Medical Association, is the first large-scale randomized controlled trial to show that organized, sustainable lifestyle interventions can have a measurable impact on brain health.
It's an important finding as the nation is on a path to double the number of people living with dementia by 2060. About 10% of Americans over age 65 have been diagnosed with dementia, according to the Centers for Disease Control and Prevention. Nearly 7 million people in the U.S. have Alzheimer's, the most common type of dementia.
While some drugs may slow how quickly dementia develops, there is no cure.
'Some people are scared, thinking there's nothing you can do' to ward off dementia, said Dr. Richard Isaacson, a neurologist and researcher at the Institute for Neurodegenerative Diseases in Florida.
The new findings, he said, show that 'we're not powerless in the fight against cognitive decline and Alzheimer's disease.' Isaacson, who formerly directed the Alzheimer's Prevention Clinic at NewYork-Presbyterian/Weill Cornell Medical Center, was not involved with the new research.
This isn't the only study to link lifestyle to a delay in dementia.
Other research presented at the Alzheimer's Association conference Monday found that regular walking can protect the brains of people with a genetic risk for Alzheimer's.
The beauty of lifestyle interventions now proven to help keep cognition sharp is that they can be applied universally, said Rachel Wu, an associate professor of psychology who researches cognition in older adults at the University of California, Riverside.
'There's no downside, no side effects to doing this stuff, except just the time it takes,' Wu said.
POINTER trial researchers also took blood samples and scanned participants' brains, looking for amyloid and tau, proteins associated with Alzheimer's disease that form plaques and tangles in the brain.
Those samples will be included in a future analysis of study participants, said Heather Snyder, a POINTER researcher and senior vice president of medical and scientific relations at the Alzheimer's Association.
'If you have this biology, do you see a better response? Less response?' she said. 'That's the kind of meaningful question we're going to be able to ask with this data.' Additional findings are expected within the year, Snyder said.
Jones is eager to see those results when they're available.
'I don't know what they saw in my brain, but I know I'm a different person,' Jones said. She's lost 30 pounds and is no longer considered prediabetic or a candidate for statins to reduce her cholesterol.
'I'm going to keep moving, eating right, socializing, monitoring my comorbidities,' she said. 'I'm going to take care of myself.'
This article was originally published on NBCNews.com
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Study Finds Special Brain Traits of 'SuperAgers.' Here's How They Avoid Dementia
A study that began in the year 2000 is finally paying off. Northwestern University's SuperAger program has been in the works for over 25 years, and a new report in the Journal of the Alzheimer's Association is detailing what the group has found. Published on August 7, the report details the scope of the study and its results so far — 25 years out since the start. 290 people signed up to be studied in that time, all over 80 years old and cognitively well. Participants are tested for a high delayed word recall ability, signifying a higher memory capacity at an older age. These seniors that show exceptional memory are labeled "SuperAgers". Of the 290 participants, 79 allowed scientists to autopsy their brains after passing away. Because of this, researchers were able to make a connection between dementia, particularly Alzheimer's, and the structure of the brain. "Neurotypical seniors ≥ 80 years of age have significant and widespread cortical thinning compared to neurotypical 50- to 60-year-olds," the report reads, "Superagers, on the other hand, showed no cortical thinning compared to the younger controls." The brain — particularly the cerebral cortex — naturally thins as a person ages, but Northwestern's report shows that may happen less quickly in some people than in others. "It appears that cortical thinning is unavoidable," the report states, "but that it is probably much slower in superagers." Further, researchers reported that superagers' brains tend to develop few or zero amyloid plaques and tau tangles, which are two tell-tale signs of Alzheimer's disease. While no specific cause has been determined, researchers believe they're a bit closer to understanding dementia. What is dementia? Dementia is a decline in memory or mental capacity, usually found in senior citizens. Alzheimer's is the most common form of dementia, affecting around 11% of those 65 and older. There are various factors that scientists believe could lead to an increased chance of developing Alzheimer's or dementia as a person ages. Some of these factors, as found in the study by Northwestern University, are structural and genetic. Others, though, may come from a person's lifestyle. Research shows that traumatic brain injuries earlier in life, high blood pressure, untreated depression, and hearing loss may help onset dementia. Low physical activity and few meaningful personal connections may also exasperate the degenerative Finds Special Brain Traits of 'SuperAgers.' Here's How They Avoid Dementia first appeared on Men's Journal on Aug 7, 2025 Solve the daily Crossword


Business Insider
a day ago
- Business Insider
Heartflow Stock (HTFL) Jumps 50% in Market Debut as IPOs Heat-Up
The stock of medical imaging and diagnostics software company Heartflow jumped 50% in its market debut on Aug. 8; the latest sign of red-hot demand for initial public offerings (IPOs). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Heartflow, which trades on the Nasdaq Composite exchange under the ticker symbol 'HTFL,' raised $317 million from the sale of 16.7 million shares at a price of $19 each. Demand for the share issuance was stronger than expected on Wall Street. However, the company's shares began trading on the Nasdaq at $28, nearly 50% above their offering price. The company is worth about $2.5 billion at its current share price. Bain Capital and Wellington Management are top shareholders of Heartflow. Losing Money Heartflow is the latest in a string of IPOs that have been oversubscribed and risen sharply on their first day of trading. Other hot IPOs in recent months have included AI start-up CoreWeave (CRWV), stablecoin issuer Circle (CRCL), and space exploration firm Firefly Aerospace. Heartflow's IPO looks to be a success despite the fact that the company is not yet profitable, and its losses widened in both 2024 and the first quarter of 2025. But the company's sales have grown at a brisk pace, rising 44% last year and 39% in the first three months of 2025. Analysts say the IPO market is reawakening after being dormant for the past three years. Is HTFL Stock a Buy? It's too early for any analyst to cover Heartflow's stock. So instead, we'll look at the performance of the SPDR S&P 500 ETF Trust (SPY), which tracks the benchmark U.S. stock index. As one can see in the chart below, the S&P 500 has gained 9% this year.


New York Post
a day ago
- New York Post
Trump can rein in healthcare costs AND win medical breakthroughs — here's how
Of all the problems bedeviling the American healthcare system, the high cost of pharmaceuticals is one of those most commonly cited by patients. Polling finds that most Americans think drugs are too expensive, and they're often right — even if pricey medications beat alternatives like surgery, hospitalization or living with pain. President Donald Trump has promised to implement healthcare reforms that both increase innovation and improve affordability. Advertisement Some see these as contradictory pursuits — but when it comes to pharmaceuticals, both of the president's goals can be achieved at the same time. This week the two of us, along with a team of top health and economic experts, launched Most Favored Patients, a working group aimed at developing reforms that will lower drug prices in ways that won't hinder or delay new drug development. Before we suggest policies that could work, let's be clear about what doesn't: government-mandated price controls. Advertisement Top-down edicts that remove the profit motive from drug research and development will do more harm than good, impeding the race to identify cures for cancer, Alzheimer's, Parkinson's, epilepsy and other cruel diseases. It's a short-sighted solution, too: It ignores the reality that 93% of US prescriptions are for very cheap generics — indeed, cheaper here than abroad — that emerge after innovators earn the necessary returns on their investments. Instead, let's try some innovations that make both medical and economic sense. First, do the easy stuff first and allow patients to buy medicines from pharmaceutical companies directly. Advertisement Our recent poll of 1,000 battleground-state voters found overwhelming 86% support for this concept, which would lower drug prices by avoiding expensive retail markups imposed by insurance companies and others. Most voters also favor Trump's intention to rein in costly middlemen like the highly concentrated pharmacy benefit manager industry, which negotiates drug prices for insurance companies. We also must require foreign countries to pay their fair share for medical innovations developed in the United States — that is, nearly all of them. Trump can use his NATO negotiations as a model here: Just as he has required Europe to pony up more for the benefits of NATO security through minimum levels of military spending, he could convince trading partners to spend more of their GDP on new drugs. Advertisement Right now, more than 70% of global pharmaceutical earnings come from the United States, even though we generate less than a quarter of global GDP. We annually spend $13,000 on healthcare per capita, while the rest of the developed world spends far less than $10,000 — partly because we allow more free-market healthcare pricing than other nations do. Trump is already implementing some of these reforms in his America First trade deals, securing some $300 billion worth of foreign commitments for new domestic pharmaceutical R&D, manufacturing and workforce investments. These commitments share the burden of finding cures that will benefit all of humanity — while fueling the American research engine that justifies the investments. Next, the Food and Drug Administration must thoroughly overhaul its antique, snail's-pace drug approval process: Many potential wonder drugs developed by small biomedical firms are shelved when that process' exorbitant costs and delays drain their capital. The FDA should fast-track experimental drugs for crippling and lethal diseases, and should expedite 'Right To Try' rules to get promising drugs to the people who need them. In addition, we believe the FDA should loosen its regulations and use economic criteria, not just clinical ones, to determine whether a drug may be fast-tracked for approval: Put simply, cheaper drugs should be allowed to come to market faster. Advertisement Finally, we're confident that price transparency in drugs and all other medical services would help drive prices down and encourage more comparison-shopping by patients. We don't buy food or gas or homes without knowing their price — but that's too often the case with drugs, hospitals and medical procedures. Republicans have been missing out on the political benefits of seizing on common-sense reforms like these. Advertisement Voters consistently view the GOP as being less caring and less reliable on solving our nation's healthcare concerns. That's made them cower. They keep their mouths shut and flee from any discussion of voters' valid complaints — and often lose elections as a result. As the midterms approach, Republicans who promote innovation with our Most Favored Patient proposals will help bring down costs, ensure American biomedical innovative supremacy, and save lives. Advertisement Everyone is on board with that. Stephen Moore is a co-founder of Unleash Prosperity, where Tomas Philipson is a senior research fellow.